Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 913-920, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbany, G.
Right arrow Articles by Landegren, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbany, G.
Right arrow Articles by Landegren, U.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2000;46:913-920.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Manifold-assisted Reverse Transcription-PCR with Real-Time Detection for Measurement of the BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia Patients

Gisela Barbany1,a, Anette Hagberg2, Ulla Olsson-Strömberg1, Bengt Simonsson1, Ann-Christine Syvänen1 and Ulf Landegren1,2

1 Department of Medical Sciences and
2 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden.
a Author for correspondence. Fax 46-18-553601; e-mail gisela.barbany{at}medsci.uu.se

Background: BCR-ABL fusion mRNA expression in bone marrow or peripheral blood can be used as a measure of minimal residual disease in patients with chronic myeloid leukemia (CML).

Methods: We used an oligo(dT)-coated manifold support to capture the mRNA directly from the cell lysate. After reverse transcription, the cDNA was eluted from the manifold support, and BCR-ABL and GAPDH mRNAs were quantified in real time using the TaqMan fluorogenic detection system.

Results: The detection limit of the method was one positive K562 cell among 105 negative cells. GAPDH was chosen as a reference gene based on the low variation between samples from different stages of the disease and the low signal in the absence of reverse transcription. The day-to-day variation of the method (CV) was 32%. In 43 blood samples from 13 CML patients, mRNA quantification agreed well with cytogenetic data.

Conclusions: The proposed procedure constitutes a reproducible and sensitive BCR-ABL mRNA quantification method and is suitable to monitor minimal residual disease in CML patients.




The following articles in journals at HighWire Press have cited this article:


Home page
 BloodHome page
T. Nakanishi, K. Shiozawa, B. A. Hassel, and D. D. Ross
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Blood, July 15, 2006; 108(2): 678 - 684.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. L. Nashed, K. W. Rao, and M. L. Gulley
Clinical Applications of BCR-ABL Molecular Testing in Acute Leukemia
J. Mol. Diagn., May 1, 2003; 5(2): 63 - 72.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Barbany, M. Hoglund, B. Simonsson, and the Swedish CML Group
Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy
N. Engl. J. Med., August 15, 2002; 347(7): 539 - 540.
[Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
H. Chisaka, E. Morita, K. Murata, N. Ishii, N. Yaegashi, K. Okamura, and K. Sugamura
A transgenic mouse model for non-immune hydrops fetalis induced by the NS1 gene of human parvovirus B19
J. Gen. Virol., February 1, 2002; 83(2): 273 - 281.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. Bagg
Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic Monitoring
J. Mol. Diagn., February 1, 2002; 4(1): 1 - 10.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Masui, R. Hosotani, S. Tsuji, Y. Miyamoto, S. Yasuda, J. Ida, S. Nakajima, M. Kawaguchi, H. Kobayashi, M. Koizumi, et al.
Expression of METH-1 and METH-2 in Pancreatic Cancer
Clin. Cancer Res., November 1, 2001; 7(11): 3437 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. A. Foy and H. C. Parkes
Emerging Homogeneous DNA-based Technologies in the Clinical Laboratory
Clin. Chem., June 1, 2001; 47(6): 990 - 1000.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.